After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Phillips Medisize parent company Molex has completed its acquisition of Vectura from a subsidiary of cigarette maker Philip ...

"The acquisition of Vectura reflects our commitment to advancing industry-leading medical capabilities for our customers," said Joe Nelligan, CEO, Molex, which acquired Phillips Medisize in 2016.

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of ...

A top doctor has revealed which common medications taken by millions could put you at risk of a heart attack. Dr Zain Hasan, an anesthetist in California, highlighted non-steroidal anti ...

Several major pharmaceutical companies, including Pfizer, Bristol Myers Squibb and Sanofi, are set to raise prices on more than 250 branded medications in the U.S. starting Jan. 1, 2025 ...